All procedures involving animal models have been reviewed by the local institutional animal care committee and the JoVE veterinary review board.
1. General Animal and Surgical Preparation
- Before starting the surgical procedure, thaw the virus (AAV9-UBI-GFP [UBI: Ubiquitin Promoter, GFP: Green Fluorescent Protein]; 5 µL aliquots). Prepare a 5% dextran (10,000 MW) solution by mixing dextran powder in distilled water. Mix the virus solution with 5% dextran solution 1:1 to a final dextran concentration of 2.5%.
- Store the virus solution on ice (4 °C).
- Use adult C57BL/6J mice (male and female, 20-30 g). Anesthetize the mice using 5% isoflurane (in O2, 1 L/min) and maintain them at 2-3% inhaled isoflurane (in O2, 1 L/min) by nose cone during surgery, depending on the breathing rate and paw pinch response.
- Shave the back of the animals with shaving clippers and clean the skin with 2% chlorhexidine.
- In chronic recovery studies, follow a strict sterile technique.
- If lumbar subpial injections are to be performed, cut the skin overlaying the Th8-L1 vertebrae with a scalpel and detach the paravertebral muscle from Th10-12 spinal vertebrae using scissors.
- Mount the animal into a standard stereotaxic frame using mouse spinal clamps.
- Shave both sides of the lamina of the Th10-12 vertebrae using a dental drill (drill bit: 0.9 mm, speed: 20,000 rpm) until cracks appear.
- Remove cracked bone fragments with forceps and expose the dorsal surface of the lumbar spinal cord.
- Cut open the dura about 1 cm using a 30 G stainless steel needle and forceps.
2. Opening the Pial Membrane and Inserting the Subpial Needle for AAV9 Delivery
- Mount the 34 G pia-penetrating needle into the Z-arm of an XYZ manipulator using a glass capillary holder (Figure 1A and B).
NOTE: To manufacture the pia-penetrating needle, the original beveled tip of the 34G needle is sharpened using a glass capillary beveller with diamond abrasive plate - coarse (5.0 µm to 50 µm tip sizes) and grinding angle of 15 - 20°. The tip of the needle (1 mm length, measured from the tip) is then gently bent to about 90° (Figure 1B, left insert). - Using a surgical dissecting scope, set to 8-10X magnification, penetrate the pia with the pia-penetrating needle by about 1 mm (Figure 1C) using the X-arm.
- Keep the angle of the penetrating needle to the tissue surface at 5-10°.
- After the pia opening, remove the pia-penetrating needle horizontally from the subpial space (Figure 1D) using the X-arm.
NOTE: Remember the penetrated site by a landmark, such as a blood vessel. - Load a blunt 36G injection needle with AAV9-UBI-GFP virus using a 50-µL microsyringe connected to the injection needle with PE-10 or PE-20 tubing.
- Mount the needle into the Z-arm of a second XYZ manipulator (Figure 1A and B) using a glass capillary holder (Figure 1B, right insert).
NOTE: To manufacture the subpial AAV9 injection needle, the blunt tip of a 36 G needle is polished using a glass capillary beveler with diamond abrasive plate - coarse (5.0 µm to 50 µm tip sizes) to remove the sharp edges. The tip of the needle (2-3 mm length, measured from the tip) is then gently bent to about 90°. The pia-penetrating and subpial injection needles are inserted into 1-2 cm-long 20G slave stainless steel tubing (10 mm from the end of the needle) and glued with epoxy. The use of 20 G (0.91 mm-diameter) tubing is required for a secure attachment to the glass capillary holder. - By manipulating the X, Y, and Z arms of the second manipulator, position the tip of the AAV9 injection needle into the pia-penetrated site and then advance it about 2-3 mm into the subpial space through the previous pial membrane opening using the X-arm ( Figure 1E and F).
NOTE: 1) The AAV9-UBI-GFP is prepared according to previously reported protocols, and the final titers are adjusted to 1.2 x 1013 genome copies per mL (gc/mL). 2) There is no need to mark the site of the pial opening because it is readily identifiable (Figure 1D). - Inject the AAV9-UBI-GFP (1.5, 3, or 5 µL) into the subpial space using a 50 µL microsyringe (see Table 1 for experimental groups).
- Remove the injection needle from the subpial space after the AAV9-UBI-GFP injection is complete.
- Close the muscle and skin using 4.0 monofilament suture and surgical clips.
NOTE: There is no need to seal the open vertebra. - Allow the animals to recover on a heating pad.
- For pain control, inject Buprenorphine 0.05 mg/kg/sc every 12 h for 2-3 days post-surgery.
Table 1: Experimental Groups. All experiments were performed in adult C57BL/6J mice.
| Experimental Groups | Site/level of AAV9 delivery (*) | Volume of AAV9 inj, infusion rate | Survival time | Tissue analysis |
| Group A (n = 7) | C2 (bilateral) | 5 µL/5 min | 14 days | Brain + spinal cord |
| Group B (n = 12) | L1-L2 (bilateral) | 1.5 µL or 3µL, 60 sec/µL | 14 days | Brain + spinal cord |
| Group C (n = 6) | C2 + L1-L2 (bilateral at each level) | 5 µL/5 min | 14 days | Spinal cord |
| * - bilateral = two subpial injections, one delivered into the right and one to the left subpial space of the injected segment(s) are performed. |